Improved Outcome for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL) Who Stop Ibrutinib +/− Rituximab for Reasons Other Than Progression of Disease

Hematological Oncology - United Kingdom
doi 10.1002/hon.2439_114
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Long-Term Outcomes and Mutation Profiling of Patients With Mantle Cell Lymphoma (MCL) Who Discontinued Ibrutinib

British Journal of Haematology
Hematology
2018English

Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Annals of Hematology
MedicineHematology
2013English

Phase 2 Trial of Rituximab and Bortezomib in Patients With Relapsed or Refractory Mantle Cell and Follicular Lymphoma

Cancer
Cancer ResearchOncology
2010English

Comparative Effectiveness of Treatments for Relapsed or Refractory Mantle Cell Lymphoma (R/R McL), Using Matching Adjusted Indirect Comparison

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Outcome of Patients With Relapsed and Refractory Peripheral T Cell Lymphoma Intended for Stem Cell Transplant

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Combination of Ibrutinib With Rituximab (Ir) Is Highly Effective in Previously Untreated Elderly (>65 Years) Patients (Pts) With Mantle Cell Lymphoma (Mcl) - Phase Ii Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Durable Response With Single-Agent Acalabrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2019English

Outcomes in First Relapsed-Refractory Younger Patients With Mantle Cell Lymphoma: Results From the Mantle-First Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy